IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by 1832 Asset Management L.P.

1832 Asset Management L.P. reduced its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 46.7% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 79,740 shares of the medical research company’s stock after selling 69,997 shares during the period. 1832 Asset Management L.P.’s holdings in IQVIA were worth $20,165,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Team Hewins LLC raised its holdings in shares of IQVIA by 5.0% during the first quarter. Team Hewins LLC now owns 973 shares of the medical research company’s stock worth $246,000 after purchasing an additional 46 shares during the last quarter. Covestor Ltd raised its holdings in shares of IQVIA by 45.3% during the first quarter. Covestor Ltd now owns 154 shares of the medical research company’s stock worth $39,000 after purchasing an additional 48 shares during the last quarter. Jag Capital Management LLC raised its holdings in shares of IQVIA by 0.4% during the fourth quarter. Jag Capital Management LLC now owns 11,401 shares of the medical research company’s stock worth $2,638,000 after purchasing an additional 49 shares during the last quarter. Raleigh Capital Management Inc. raised its holdings in shares of IQVIA by 4.5% during the fourth quarter. Raleigh Capital Management Inc. now owns 1,157 shares of the medical research company’s stock worth $268,000 after purchasing an additional 50 shares during the last quarter. Finally, Cypress Wealth Services LLC raised its holdings in shares of IQVIA by 5.3% during the first quarter. Cypress Wealth Services LLC now owns 1,101 shares of the medical research company’s stock worth $278,000 after purchasing an additional 55 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on IQV. Jefferies Financial Group cut shares of IQVIA from a “buy” rating to a “hold” rating and reduced their target price for the stock from $266.00 to $242.00 in a report on Wednesday. The Goldman Sachs Group began coverage on shares of IQVIA in a report on Thursday, June 6th. They issued a “buy” rating and a $270.00 price objective for the company. StockNews.com raised shares of IQVIA from a “hold” rating to a “buy” rating in a report on Monday, July 15th. UBS Group lifted their price objective on shares of IQVIA from $295.00 to $300.00 and gave the company a “buy” rating in a report on Tuesday, July 23rd. Finally, Morgan Stanley lifted their price objective on shares of IQVIA from $270.00 to $280.00 and gave the company an “overweight” rating in a report on Tuesday, July 23rd. Four research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, IQVIA has a consensus rating of “Moderate Buy” and a consensus price target of $263.56.

IQVIA Price Performance

IQV traded up $7.38 on Friday, reaching $239.67. 1,195,238 shares of the company’s stock were exchanged, compared to its average volume of 1,420,984. The stock has a market cap of $43.69 billion, a PE ratio of 32.74, a P/E/G ratio of 2.26 and a beta of 1.49. IQVIA Holdings Inc. has a twelve month low of $167.42 and a twelve month high of $261.73. The stock’s fifty day moving average price is $220.23 and its 200-day moving average price is $229.46. The company has a debt-to-equity ratio of 1.80, a current ratio of 0.85 and a quick ratio of 0.88.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Monday, July 22nd. The medical research company reported $2.64 earnings per share for the quarter, topping analysts’ consensus estimates of $2.57 by $0.07. The firm had revenue of $3.81 billion for the quarter, compared to analyst estimates of $3.79 billion. IQVIA had a net margin of 9.39% and a return on equity of 28.59%. IQVIA’s quarterly revenue was up 2.3% on a year-over-year basis. During the same period in the previous year, the business posted $2.22 earnings per share. Sell-side analysts expect that IQVIA Holdings Inc. will post 10.21 EPS for the current year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.